国: 南アフリカ
言語: 英語
ソース: South African Health Products Regulatory Authority (SAHPRA)
Nbi
RABIGAM® IM REGISTRATION NUMBER T/30.2/748 PROPRIETARY NAME (and dosage form) RABIGAM ® IM (Solution for Intramuscular Injection) DESCRIPTIVE NAME OF MEDICINE Human rabies immunoglobulin PHARMACOLOGICAL CLASSIFICATION A 30.2 Biologicals (Antibodies) SCHEDULING STATUS S4 COMPOSITION Rabigam IM contains gammaglobulin derived from pooled human plasma, sourced from non-remunerated healthy donors, with a high titre of antibodies to the rabies virus. Each unit of plasma has been individually testedand found non-reactive for hepatitis B surface antigen, antibodies to the hepatitis C virus and antibodies to the human immunodeficiency viruses, HIV-1 and HIV-2, using approved methods. Rabigam IM is prepared by cold ethanol fractionation to further reduce the risk of viral transmission. Each 2 mL ampoule contains 300 IU (150 IU/mL) rabies virus antibodies. This preparation contains no antimicrobial preservative and is stabilised with glycine. IDENTIFICATION A clear, pale yellow or light brown liquid exhibiting a slight opalescence. PHARMACOLOGICAL ACTION OF THE MEDICINE Rabies immunoglobulin confers passive immunity against rabies. The pharmacodynamic effects in vivo of the specific neutralising antibodies against rabies virus are not fully documented, but rabies immunoglobulin has been proven to be effective in preventing the rabies infection. INDICATIONS Rabies immunoglobulin (passive immunisation) is indicated for all persons known or suspected to have been exposed to the rabies virus and is used in conjunction with the rabies vaccine (active immunisation). Rabies immunoglobulin must be given for any mucous membrane exposure to saliva i.e. licks, and all single and multiple bites or scratches inflicted by a suspected rabid animal, especially if associated with any signs of bleeding, irrespective 完全なドキュメントを読む